Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
Executive Summary
Citing changing therapeutic landscape and doubts about utility of checkpoint inhibitor monotherapy in this setting, advisory committee votes 6-2 against maintaining PD-1 inhibitor’s accelerated approval for third-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
You may also be interested in...
Merck & Co.’s Keytruda Bounces Back In Advanced Gastric Cancer With Pivotal Success
The US major’s Keytruda has succeeded in a first-line advanced HER2-negative gastric cancer trial, which could help expand its label to a larger population and marks a positive reverse to past troubles in the indication.
Yo-Yo Approvals? Maybe Accelerated Approval Isn’t Fixed After All
Oncopeptides’ reversal on Pepaxto may or may not prove to be the right decision – but it underscores the inherent limits to US FDA’s efforts to police ‘dangling’ accelerated approvals.
Keeping Track Of Withdrawals: Libtayo, Parsaclisib Applications Pulled Due To Postmarketing Issues
Changing therapeutic landscape may have complicated regulatory plans for Regeneron/Sanofi’s PD-1 inhibitor in second-line cervical cancer, while accelerated approval confirmatory trial timeline appears to have been an issue for Incyte’s PI3-kinase inhibitor in lymphoma.